Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICT01 Monotherapy and in Combination With Pembrolizumab in Advanced Cancer
NCT04243499Phase 2Active, not recruiting
- Sponsor
- ImCheck Therapeutics
- Start
- Mar 2020
- Primary completion
- Oct 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of Ichnocim in solid tumor, hematologic malignancy, sponsored by ImCheck Therapeutics. Started Mar 2020; status: active, not recruiting.
02
Drugs
Ichnocim
03
Conditions
solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT04243499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04243499.